Pharmacists can collaborate with oncologists to maximize patient outcomes through appropriate dispensing, side-effect monitoring, and adherence.
Todd Cooperman, PharmD, RPh, PAHM
Advertisement
Articles by Todd Cooperman, PharmD, RPh, PAHM
Researchers assess new study models and investigate triple drug therapies to fight hepatitis C infection.
The blood modifier category of drugs works stimulating bone marrow to produce more cells and they affect certain diseases such as cancer and chronic kidney failure.
The next evolutionary step for specialty medications could lead to a new generation of cost-effective, noninvasive treatments for heart disease.
Newer pharmaceutical agents for the treatment of type 2 diabetes suggest a movement toward diabetes becoming a specialty disease state.
Pharmacists can collaborate with oncologists to maximize patient outcomes through appropriate dispensing, side-effect monitoring, and adherence.
Advertisement
Latest Updated Articles
- Challenges and Opportunities with Oral Oncology Agents
Published: March 24th 2011 | Updated:
- Specialty Pharmaceuticals: Hepatitis C Update
Published: February 8th 2011 | Updated:
- Specialty Pharmaceuticals: Self-Injectable Biologic DMARDs for the Treatment of Rheumatoid Arthritis
Published: September 28th 2010 | Updated:
- Specialty Pipeline for the Treatment of Type 2 Diabetes Mellitus
Published: October 24th 2010 | Updated:
- Specialty Pharmaceuticals: Challenges and Opportunities with Oral Oncology Agents
Published: August 17th 2010 | Updated:
- Gene Therapy for Heart Disease
Published: December 13th 2010 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
A Review of Antibody-Drug Conjugates for the Treatment of Urothelial Carcinoma: The Rise of Enfortumab Vedotin
2
Oral Semaglutide Shows Promise for Weight Loss and Cardiometabolic Health
3
Low-Dose Aspirin Linked to Lower Cardiovascular Risk in Type 2 Diabetes
4
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
5
